Document is current
Any future updates will be listed below
-
Authors
Nagano, China https://orcid.org/0000-0003-4946-1345
Matuso, Masafumi
Inoki, Yuta
Tanaka, Yu
Ichikawa, Yuta
Ueda, Chika
Kitakado, Hideaki
Sakakibara, Nana
Horinouchi, Tomoko
Yamamura, Tomohiko
Ishimori, Shingo
Nozu, Kandai
-
Funding
Funding for this research was provided by:
the Ministry of Education, Culture, Sports, Science and Technology of Japan (20K16926, 23K07698)
Health, Labour and Welfare Sciences Research Grants (23FC1047)
the Japan Agency for Medical Research and Development (24015773, 22810094, 23ek0109617s1702)
Kobe University
- License Information
-
More Information
Article History
Received: 6 February 2025
Accepted: 2 June 2025
First Online: 10 June 2025
Declarations
:
: Kandai Nozu is a member of advisory groups for Kyowa Kirin Co. Ltd., Toa Eiyo Ltd., Zenyaku Kogyo Co. Ltd., and Taisho Pharmaceutical Co. Ltd. Kandai Nozu received lecture fees from Ono Pharma, Astellas Pharma, Novo Nordisk Pharma, Alexion Pharma, Sumitomo Pharma, Sanofi, Otsuka Pharma, Daiichi Sankyo, and Miyarisan. Kandai Nozu received a grant from Zenyaku Kogyo and Torii Co. Ltd. Tomoko Horinouchi received research funding from Otsuka Pharmaceutical Co., Ltd., Sysmex Corporation, and Zenyaku Kogyo Co., Ltd. The other authors have nothing to disclose.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of Kobe University Graduate School of Medicine (IRB approval number 301) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all participants included in the study.
: Informed consent was obtained from all individual participants included in the study.
